Targeting the toxic alpha-synuclein protein found in the brains of people with Parkinson’s is one of the most promising approaches to treat the disease in the clinic – but getting any drug into the brain is a challenge. Sanofi SA has joined with ABL Bio Inc. to solve this problem, in-licensing ABL-301, a preclinical bispecific antibody that locks on to misfolded alpha-synuclein but also includes a molecular “shuttle” that allows it to penetrate the blood-brain barrier.
Shanghai-based Everest Medicines Ltd. has won exclusive global rights to a set of viral 3C-like (3CL) protease inhibitors from Singapore's national drug discovery platform, the Experimental Drug Development Centre (EDDC), in a deal worth up to $214.5 million.
LONDON – Evotec SE put the biggest ever headline figure on one of its pharma drug discovery collaborations, announcing a $1 billion deal with Eli Lilly and Co. in metabolic diseases. The Hamburg, Germany-based company will be responsible for the discovery of drug candidates for the treatment of diabetes and chronic kidney disease against targets identified by Lilly or Evotec, or sourced externally. Lily has rights to up to five programs, to be developed in the partnership and to take on any subsequent development, clinical validation and commercialization activities. The collaboration initially runs for three years.
SCG Cell Therapy Pte. Ltd. has acquired rights to human induced pluripotent stem cell technology from Singapore’s Agency for Science, Technology and Research (A*STAR)’s Accelerate Technologies Pte. Ltd. to support the development of natural killer (NK) cell therapies for leukemia, liver cancer, gastric cancer and other solid tumors.
Shanghai-based Everest Medicines Ltd. has won exclusive global rights to a set of viral 3C-like (3CL) protease inhibitors from Singapore's national drug discovery platform, the Experimental Drug Development Centre (EDDC), in a deal worth up to $214.5 million.
SCG Cell Therapy Pte. Ltd. has acquired rights to human induced pluripotent stem cell technology from Singapore’s Agency for Science, Technology and Research (A*STAR)’s Accelerate Technologies Pte. Ltd. to support the development of natural killer (NK) cell therapies for leukemia, liver cancer, gastric cancer and other solid tumors.
Viveon Health Acquisition Corp. (VHAQ) reported a merger deal with regenerative aesthetics company Suneva Medical Inc. According to the terms of the deal, the special purpose acquisition company (SPAC), will issue 25 million shares and up to 12 million earnout shares to Suneva shareholders. The pro forma equity valuation of the companies is expected to be approximately $511 million, with the merger slated for completion in the first half of 2022.
Salarius Pharmaceuticals Inc. is joining the red-hot protein degradation space with an acquisition of a portfolio of oral small-molecule protein degraders and IP from Deuterx LLC it’s calling "transformative." The lead asset, SP-3164, is a cereblon-binding molecular glue that Salarius plans to move to the clinic in 2023 as a potential treatment for hematological cancers and solid tumors. Salarius paid Deuterx $1.5 million in cash and 1 million shares of restricted stock (NASDAQ:SLRX) up front, worth about $487,900 at market close on Jan. 13.
Sana Biotechnology Inc. has acquired rights to two CAR T constructs through a pair of deals, one with partners Innovent Biologics Inc. and Iaso Biotherapeutics Co. Ltd. and a second with the U.S.-based National Cancer Institute (NCI). In the Innovent-Iaso deal, Sana secured nonexclusive commercial rights to a B-cell maturation antigen-targeted CAR T construct for in vivo gene therapy and ex vivo hypoimmune cell therapy applications. The NCI deal, for exclusive commercial rights to the NCI’s CD22 CAR asset, could help Sana “address key relapse challenges for CD19-directed CAR T-cell therapies,” the company said.
Astrazeneca plc has announced two significant R&D deals with Scorpion Therapeutics Inc. and Benevolentai Ltd., which it hopes will sharpen its research into cancer, lupus and heart failure. Both of the deals involve artificial intelligence (AI) as a way to increase the probability of success during the clinical development process and reduce the chances of costly trial failures.
RSS
